Are there any drug interactions between lisdexamfetamine (Vyvanse) and sulfamethoxazole‑trimethoprim (Bactrim)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

No Clinically Significant Interaction Between Vyvanse and Bactrim

There is no documented clinically significant drug interaction between lisdexamfetamine (Vyvanse) and sulfamethoxazole-trimethoprim (Bactrim), and these medications can be safely co-administered in most patients.

Key Considerations

Direct Drug Interaction Evidence

The available evidence does not identify any direct pharmacokinetic or pharmacodynamic interaction between these two medications:

  • Lisdexamfetamine is a prodrug that is hydrolyzed in the blood to d-amphetamine, which then acts on dopamine and noradrenaline transporters 1
  • Bactrim (TMP-SMX) primarily inhibits CYP2C8 (trimethoprim) and CYP2C9 (sulfamethoxazole) 2
  • Amphetamines are not significantly metabolized through these cytochrome P450 pathways—approximately 80% of methylphenidate metabolism is extrahepatic 3, and lisdexamfetamine's conversion to d-amphetamine occurs via hydrolysis in red blood cells, not hepatic metabolism

Cardiovascular Monitoring Remains Important

While no interaction exists, both medications have cardiovascular considerations that require standard monitoring:

For Lisdexamfetamine:

  • Monitor heart rate and blood pressure regularly 4
  • Contraindicated in uncontrolled hypertension, hyperthyroidism, and with MAOIs 4
  • Risk of peripheral vasculopathy including Raynaud's phenomenon 5

For Bactrim:

  • Sulfamethoxazole can cause QT prolongation and torsades de pointes in rare cases, particularly in patients with genetic polymorphisms affecting potassium channels 6
  • This risk is independent of lisdexamfetamine use

Practical Clinical Approach

When co-prescribing these medications:

  1. Baseline assessment: Check blood pressure and heart rate before initiating lisdexamfetamine (standard practice regardless of Bactrim use)

  2. Monitor cardiovascular parameters: Continue routine monitoring as you would for any patient on stimulant therapy—no additional monitoring is needed specifically for the combination

  3. Watch for additive cardiovascular effects: While not a true drug interaction, be aware that if a patient develops tachycardia or hypertension, either medication could be contributing

  4. No dose adjustments needed: Neither medication requires dose modification when used together

Common Pitfalls to Avoid

  • Do not confuse with MAOI interactions: Lisdexamfetamine is contraindicated with MAOIs (risk of hypertensive crisis) 4, but Bactrim is not an MAOI
  • Do not confuse with warfarin interactions: Bactrim has significant interactions with warfarin 7, 8, 9, but this is irrelevant to lisdexamfetamine
  • Do not confuse with serotonergic interactions: While lisdexamfetamine carries a warning about serotonin syndrome 5, this occurs with serotonergic agents (SSRIs, MAOIs, etc.), not with Bactrim

Special Populations

Renal impairment: Both medications require dose adjustment in renal dysfunction, but these adjustments are independent of each other 7, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.